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Heavy chain diseases are rare variants of B-cell lymphomas that produce one of three classes of immunoglobulin heavy chains,
without corresponding light chains. We describe two patients with asymptomatic heavy chain monoclonal gammopathy. The first
patient is a 51-year-old woman with alpha paraprotein on serum immunofixation. The second case is a 46-year-old woman with
gamma paraprotein on urine immunofixation. Neither patient had corresponding monoclonal light chains. Workup for multiple
myeloma and lymphoma was negative in both patients. These two cases illustrate that heavy chain monoclonal gammopathy can
exist in the absence of clinically apparent malignancy. Only a few reports of “heavy chain MGUS” have been described before. In
the absence of specialized guidelines, we suggest a similar follow-up as for MGUS, while taking into account the higher probability
of progression to lymphoma than to myeloma.
1. Introduction
Heavy chain diseases are characterized by the presence of
monoclonal heavy chains without light chains in serum
and/or urine [1]. They are rare variants of B-cell lymphomas
that produce one of three classes of immunoglobulin heavy
chains: alpha, gamma, or mu [2–4]. The clinical manifes-
tations vary with the heavy chain isotype and range from
an asymptomatic presentation to aggressive lymphoma [5].
In this report, we describe two patients with asymptomatic
heavy chain monoclonal gammopathy, who meet the criteria
of “monoclonal gammopathy of undetermined significance”
(MGUS) [6].
2. Case 1
A 51-year-old woman with a past medical history of
depression and dyslipidemia was referred by her general
practitioner to the hematology consultation. During the
workup of myalgia after start of rosuvastatin therapy, an
abnormal serum protein electrophoresis was discovered. At
the time of referral, rosuvastatin was stopped and myal-
gia had disappeared. The patient was asymptomatic. Her
only medication consisted of risperidone 1mg. She never
smoked. Physical findings were normal. Laboratory findings
included hemoglobin of 14.0 g/dL, total leukocyte count of
8.4 × 109/L with normal differential count, and platelets
of 360 × 109/L. Serum creatinine was 0.62mg/dL (eGFR >
90mL/min/1.73m2) and blood urea nitrogen 10mg/dL. Cal-
cium level was normal. Liver function, lactate dehydrogenase,
creatine kinase, and coagulation tests were within normal
limits. C-reactive protein was 1.6mg/L (reference value <
5mg/L).
Serum protein electrophoresis showed a monoclonal
spike of 8.9 g/L in the beta-fraction (see Figure 1). Immun-
ofixation revealed an alpha paraprotein, without correspond-
ing monoclonal kappa or lambda chains. 24-hour urine
collection contained 0.11 g of protein, without monoclonal
spike. Serum total IgA level was 7.20 g/L.
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Figure 1: (a) Serum protein electrophoresis showing monoclonal
spike in the beta-fraction (arrow). (b) Serum immunofixation show-
ing presence of alpha paraprotein (arrow), without corresponding
kappa or lambda light chains.
Table 1: Evolution of total IgA and estimated monoclonal spike
during 8 years of follow-up.
Time (y) IgA (g/L) Estimated monoclonal
spike (g/L)
0 7.20 8.9
1 6.72 NA
2 7.08 NA
3 8.18 9.1
4 8.63 NA
5 7.72 NA
6 NA NA
7 NA NA
8 9.53 10.9
Bone marrow was normocellular with trilineage hema-
topoiesis and normal percentage of plasma and lymphoid
cells. X-ray metastatic bone survey was negative. Chest X-
ray and abdominal ultrasound showed no lymphadenopathy
or organomegaly. Upper gastrointestinal endoscopy excluded
MALT lymphoma. During 8 years of follow-up, the patient
developed hypertension and type 2 diabetes; otherwise she
remained asymptomatic. Kidney function remained stable.
Serum monoclonal spike rose from 8.9 to 10.9 g/L and total
IgA from 7.20 to 9.53 g/L (see Table 1). Urine electrophoresis
stayed negative.
Figure 2: Urinary immunofixation shows a gamma paraprotein
(arrow), without corresponding monoclonal light chains.
In conclusion, we describe an asymptomatic patient with
an incidental finding of monoclonal gammopathy, corre-
sponding to alpha heavy chains without monoclonal light
chains. As workup for lymphoma, myeloma, andmonoclonal
gammopathy related end organ damage was negative, we
diagnosed a heavy chain monoclonal gammopathy of unde-
termined significance (MGUS). During 8 years of follow-
up, serum monoclonal spike was relatively stable and urine
electrophoresis remained negative.
3. Case 2
A 46-year-old woman was referred to the nephrology con-
sultation for the investigation of chronic kidney disease, with
serum creatinine of 1.72mg/dL (eGFR: 35mL/min/1.73m2)
and blood urea nitrogen of 66mg/dL. The patient’s medi-
cal history included squamous cell carcinoma of the right
ovary, for which she had undergone extensive surgery (total
pelvic exenteration with colostomy and Bricker diversion,
sigmoid resection, and partial enterectomy), chemotherapy
(cisplatinum, 5-fluorouracil, and mitomycin C, followed by
carboplatin, etoposide, ifosfamide, and paclitaxel), and pelvic
radiotherapy. The remainder of her past medical history
was remarkable for hypertension, anemia of chronic kidney
disease, and short bowel syndrome after the aforementioned
surgery, for which she was treated with total parenteral nutri-
tion. Her medication included darbepoetin alfa 60𝜇g per 2
weeks, ramipril 5mg, barnidipine 10mg, sodium bicarbonate
4 g daily, and an estradiol patch. She never smoked. Blood
pressure was well controlled.
Serum and urine protein electrophoresis and immunofix-
ation were ordered in the workup of chronic kidney disease.
Immunofixation of the 25-fold concentrated 24-hour urine
collection showed the presence of a weak monoclonal band
typed as gamma heavy chain, without monoclonal kappa or
lambda immunoglobulin light chains (see Figure 2). Serum
electrophoresis and immunofixation were normal. Total IgG,
IgA, and IgM values were 14.40 g/L, 2.73 g/L, and 0.78 g/L,
respectively. Serum free light chains were elevated in accor-
dance with the degree of renal insufficiency: 35.00mg/L for
kappa and 35.80mg/L for lambda light chains, with a normal
kappa/lambda ratio (0.98).
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Hemogram showed a hemoglobin of 11.2 g/dL, total
leukocyte count of 5.14 × 109/L with a normal differential
count, and platelets of 125 × 109/L. Peripheral blood smear
showed no abnormal lymphocyte population. Liver function,
coagulation tests, lipid profile, and fasting and postprandial
blood sugars were within normal limits. C-reactive protein
was 1.9mg/L (reference value, < 5mg/L). Urine sediment
showed sterile pyuria and microscopic hematuria (48/𝜇L), a
normal finding given the Bricker urinary diversion. Protein-
uria on a 24-hour urine collection was 0.23 g.
Bone marrow biopsy showed normal presence of all cell
lines with a mild elevation of plasma cells (3.7%), without
an atypical morphology. Whole body computed tomography
(CT) with 18-fluorodeoxyglucose (FDG) positron emission
tomography (PET) showed no evidence of lymphoma. Ultra-
sound examination revealed relatively small kidneys (left:
99mm, right: 94mm) with bilateral significant dilatation of
the pyelocaliceal system. Kidney biopsy showed extensive
chronic destruction of renal parenchyma in a zonal pattern.
All these findings are suggestive of reflux nephropathy.There
was no evidence of cast nephropathy, amyloidosis, or heavy
or light chain deposition disease on renal biopsy.
In conclusion, we describe a patient with chronic kidney
disease due to reflux nephropathy after Bricker urinary
diversion, whose urine immunofixation showed presence of
monoclonal gamma heavy chains. Workup for lymphoma
and myeloma was negative; kidney biopsy showed no mon-
oclonal gammopathy related pathology. Since only one year
of follow-up is available, early stage Franklin’s disease cannot
be entirely excluded. No specific treatment was started.
During one year of follow-up the clinical situation remained
unchanged.
4. Discussion
Heavy chain diseases are B-cell lymphoproliferative disor-
ders that are characterized by the production of mono-
clonal immunoglobulins consisting of heavy chains without
associated light chains [1]. The diagnosis is established by
demonstration of alpha, gamma, ormu paraprotein on serum
and/or urine protein electrophoresis and immunofixation,
without corresponding monoclonal kappa or lambda chains.
One should be aware that differing sensitivity of heavy and
light chain reagents could potentially cause false negative
results of light chain immunofixation.This would incorrectly
suggest the diagnosis of heavy chain disease in a case of a
regular, intact monoclonal gammopathy.
Alpha, gamma, and mu heavy chain diseases have been
described [2–4]. Of these, alpha heavy chain disease (Selig-
mann’s disease) is the most common. It was first described in
1968 by Seligmann et al. [7], hence its eponym.Approximately
175 cases have been described. The patients typically present
with chronic diarrhea, malabsorption, and weight loss. Some
patients develop extensive mesenteric adenopathy [2]. Alpha
heavy chain disease is also known as immunoproliferative
small intestinal disease. It is a form of MALT lymphoma and
is associated with poor sanitation and Campylobacter jejuni
infection [8]. Some cases may respond to treatment with
antibiotics.Therefore an endoscopic andmicrobiologic study
of the digestive tract is indicated in the workup of alpha heavy
chain disease.
Gamma heavy chain disease is intermediate in frequency.
It is also called Franklin’s disease [9], after the author of the
first report in 1964. Since then, approximately 130 cases have
been described in the literature. The classical presentation is
one with generalized lymphadenopathy, splenomegaly, and
anemia [10]. The most distinctive symptom is palatal edema
resulting from enlargement of nodes in Waldeyer’s ring,
sometimes leading to respiratory compromise [2]. Gamma
heavy chain disease is associated with autoimmune disease
in almost one-third of cases: rheumatoid arthritis is most
common; other associated diseases include autoimmune
hemolytic anemia and idiopathic thrombocytopenic purpura
[1].
Mu heavy chain disease is the least common of the
heavy chain diseases. Less than 30 cases have been reported.
Its clinical features resemble chronic lymphocytic leukemia.
Vacuolated lymphocytes in the bone marrow are character-
istic [11]. Unlike alpha and gamma heavy chain diseases, mu
heavy chain disease can be associatedwith increased free light
chain excretion as some tumor cells seem to have a defect in
the assembly of both light and heavy chains.
We described two cases (one alpha and one gamma)
of heavy chain monoclonal gammopathy who were asymp-
tomatic. Based the low value of the monoclonal spike
(<30 g/L) and bonemarrowmonoclonal plasma cells (<10%),
absence of end organ damage, and clinical or radiographic
evidence of lymphoma, these cases met the criteria for mon-
oclonal gammopathy of undetermined significance (MGUS)
[6].
Only a few reports of “heavy chain MGUS” have been
described previously [1, 11–15]. There are no established
guidelines for follow-up. We propose the same follow-up as
for normal MGUS. However, unlike normal MGUS, there
are no validated risk factors for progression that could guide
intensity of follow-up. Note that most heavy chain diseases
are lymphoproliferative disorders. Therefore, heavy chain
MGUS is more likely to progress to lymphoma than to
myeloma. Follow-up should focus on assessment of lym-
phadenopathy and organomegaly.This can be done by regular
physical examination in most cases and imaging on indica-
tion. Follow-up should include measurement of serum and
urinary M-protein, complete blood count, creatinine, and
electrolytes. M-protein level can be determined semiquan-
titatively by protein electrophoresis and immunofixation. At
thismoment, there are no commercially available quantitative
techniques to measure monoclonal free heavy chains.
5. Conclusion
Heavy chain diseases are rare variants of B-cell lymphomas
characterized by the presence of monoclonal heavy chains,
alpha, gamma, or mu, without corresponding light chains.
Clinical presentation is diverse. We describe two asymp-
tomatic cases that meet the criteria of MGUS. This report
demonstrates that heavy chain monoclonal gammopathy can
exist in the absence of clinically apparent malignancy, similar
to other forms of MGUS. In the absence of specialized
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guidelines, we suggest a similar follow-up as forMGUS, while
taking into account the higher probability of progression to
lymphoma than to myeloma.
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